BIO KEY INTERNATIONAL INC — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
BIO-key reported Q2 2026 revenues of $1.92M (up 13% YoY), with net loss narrowing to $(577K) from $(1.17M) YoY—a 51% improvement. Gross margin expanded to 87% from 73%, driven by 53% growth in high-margin license fees ($1.23M). The company raised $2.5M gross proceeds via warrant exercise at $4.06/share (618,334 shares), issuing 1.24M new warrants at the same price, bringing cash to $4.5M. A delayed $0.8M hardware order is now expected in 2H 2026. Stockholders' equity declined to $4.33M from $5.11M due to YTD losses, but the company targets profitability in 2H 2026.
Why this rating
Material improvement in unit economics and profitability trajectory for a $4.9M market-cap company; warrant dilution and declining equity partially offset; capital raise extends runway meaningfully.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.